MYRX Stock Overview
Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Myrexis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.011 |
| 52 Week High | US$0.019 |
| 52 Week Low | US$0.0003 |
| Beta | 0 |
| 1 Month Change | 9.95% |
| 3 Month Change | 20.00% |
| 1 Year Change | 556.25% |
| 3 Year Change | -82.20% |
| 5 Year Change | -63.79% |
| Change since IPO | -99.85% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| MYRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 1.2% |
| 1Y | 556.3% | 0.7% | 24.9% |
Return vs Industry: MYRX exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: MYRX exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| MYRX volatility | |
|---|---|
| MYRX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MYRX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MYRX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Jon Couchman | www.myrexis.com |
Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.
Myrexis, Inc. Fundamentals Summary
| MYRX fundamental statistics | |
|---|---|
| Market cap | US$362.03k |
| Earnings (TTM) | -US$11.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs MYRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.62m |
| Earnings | -US$11.62m |
Last Reported Earnings
Jun 30, 2013
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MYRX perform over the long term?
See historical performance and comparison